« Back
Home /
Darovasertib

Darovasertib

Item no.	HY-101569-5mg
Manufacturer	MedChem Express
CASRN	1874276-76-2
Amount	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 25 mg 2 mg 50 mg 5 mg
Category	Oncology Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer
Type	Inhibitors
Specific against	other
Purity	99.42
Formula	C22H23F3N8O
Citations	[1]Protein Kinase C Inhibitor LXS196<br/>[2]US20180179181.
Smiles	NC1=C(C(NC2=C(N3CCC(C)(N)CC3)C=CC=N2)=O)N=C(C4=NC=CC=C4C(F)(F)F)C=N1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LXS196; IDE196
Available
Product Description	Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research[1][2].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	472.47
Clinical Information	Phase 2
Manufacturers Research Area	Cancer
Solubility	DMSO : 25 mg/mL (ultrasonic)
Target	PKC
Manufacturers Target	PKC
Isoform	PKCα; PKCθ
Manufacturers Pathway	Epigenetics; TGF-beta/Smad
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-101569-5mg-safety-datasheet.pdf